Molecule to Market: Inside the outsourcing space Raman Sehgal
-
- Vetenskap
Molecule to Market takes you inside the contract outsourcing space with industry insights and thoughts direct from the brains of the people that make the headlines (just think of your favourite podcast and that’s what we’re doing, but with drug supply chain shortages instead of unsolved crimes and life science leaders instead of sports stars). Talking everything from pharmaceutical contract research, development and manufacturing to clinical trial packaging, logistics and technology – Molecule to Market is a vital shot of infotainment for anyone who wants in on outsourcing.
-
Jumping into CDMO after a lifetime as a sponsor
In this episode of Molecule to Market, you’ll go inside the outsourcing space of the global drug development sector with Bill Humphries, CEO at Alcami.
Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with Bill, covering:
The role managers, leaders, and mentors have played in shaping his illustrious career in dermatology
The importance of ‘force multiply’ in getting results and accelerating growth
Why, after a career spent on the drug sponsor side... he decided to switch to the CDMO services side
How do the shifting sands in the sector provide a treasure trove of opportunities?
Bill Humphries, Alcami CEO, is an experienced leader in the life sciences industry, previously serving as CEO at Isosceles Pharmaceuticals, President and Group Company Chairman of Ortho-Dermatologics, CEO of Merz North America, President of Stiefel, a GSK Company and Vice President of US Skincare at Allergan Pharmaceuticals.
Bill also served as Chairman of the Board at Clearside Biomedical, Executive Chairman of Strata Skin Sciences, and a member of the Board of Directors at Aclaris Therapeutics, PhaseBio Pharmaceuticals, SKNV, and Bryn Pharmaceuticals. Humphries’ academic credentials include a B.A. from Bucknell University and an MBA from Pepperdine University.
Please subscribe, tell your industry colleagues, and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also appreciate a positive rating!
Molecule to Market is sponsored and funded by ramarketing, an international marketing, design, digital, and content agency that helps companies differentiate, get noticed, and grow in the life sciences. -
Zero to a billion... A CDMO original - part 2
In this episode of Molecule to Market, you’ll go inside the outsourcing space of the global drug development sector for part 2 of our conversation with Thomas Eldered, Executive Chairman at Flerie.
Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with Thomas, covering:
The story behind Recipharm’s decision to divest Cobra Biologics that led Thomas to become owner
How ‘big faith’ and the gene therapy revolution changed the fortunes of the loss-making biologics CDMO
After the third exit, why did he choose ‘passion rather than pension’? To fuel his love for creating things and building companies
Flerie’s mission and its patient-centric investment strategy in life sciences.
The story behind Thomas’ signature bowtie look…
Thomas Eldered was co-founder of Recipharm AB in 1995, where he served as CEO from 2008 to 2021, growing Recipharm from a local Swedish pharmaceutical contract manufacturer to an international CDMO with more than 9000 employees in 10 countries.
He was also the founder of Flerie Invest AB in 2011, where he is currently the executive chairman. Thomas is presently chairman of the board and a member of the board of several life science companies. He holds a Master of Science in Industrial Engineering and Management from Linköping University.
Please subscribe, tell your industry colleagues, and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also appreciate a positive rating!
Molecule to Market is sponsored and funded by ramarketing, an international marketing, design, digital and content agency helping companies differentiate, get noticed and grow in life sciences.
-
Zero to a billion... A CDMO original - part 1
In this episode of Molecule to Market, you’ll go inside the outsourcing space of the global drug development sector with part 1 of our episode with Thomas Eldered, Executive Chairman at Flerie.
Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with Thomas, covering:
Where his entrepreneurial spark originated, and how they created a CMO (before that was even a thing) after several failed plans
How did the timing of his first exit and having ‘cash during the crash’ fuel M&A to grow Recipharm into an international powerhouse?
Why did he decide to go public? No one else in Sweden or in the CDMO space was getting an IPO
A lifetime with Lars (his business partner) and the benefit of a partnership with aligned common interest
Why he decided to sell Recipharm after 26 years and why leaving the company was the most difficult mental decision
Thomas Eldered was co-founder of Recipharm AB in 1995, where he served as CEO from 2008 to 2021, growing Recipharm from a local Swedish pharmaceutical contract manufacturer to an international CDMO with more than 9000 employees in 10 countries. He also founded Flerie Invest AB in 2011, where he is currently Executive Chairman. Thomas is currently chairman of the board and a member of the board of several life science companies.
He holds a Master of Science in Industrial Engineering and Management from Linköping University.
Please subscribe, tell your industry colleagues, and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also appreciate a positive rating!
Molecule to Market is sponsored and funded by ramarketing, an international marketing, design, digital and content agency helping companies differentiate, get noticed and grow in life sciences. -
Dan’s the man...at Custom Biologics
In this episode of Molecule to Market, you’ll go inside the outsourcing space of the global drug development sector with Dan Mamelak, Founder & President at Custom Biologics.
Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with Dan, covering:
How reading The Billion-dollar Molecule book inspired him to explore a pathway into cutting-edge drug development
The founding story of his company and some timeless advice not to burn bridges
How the Canadian conveyor belt of intelligent, talented young science graduates has helped fuel the company’s growth
Why being privately owned has contributed to the company’s unique culture
Dan is responsible for the company's strategic direction. From the outset of his career, Dan recognized the need for solid bioanalytical expertise to support the drug discovery programs of both developing and established biopharmaceutical companies.
In 2004, Dan established Custom Biologics, a large-molecule bioanalytical CRO that designs and validates assays to measure the potency of biotherapeutic drugs, including therapeutic monoclonal antibodies and genetic therapies. Recently, the Genomics division of Custom Biologics has developed novel isothermal nucleic acid molecular diagnostic tests to rapidly identify human and food-borne pathogens.
Before founding Custom Biologics, Dan was a Senior Scientist at Affinium Pharmaceuticals, an established company that accelerates the development of small molecules into new medicines. Dan holds a Ph.D. in Biochemistry from the University of Toronto.
Please subscribe, tell your industry colleagues, and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also appreciate a positive rating!
Molecule to Market is sponsored and funded by ramarketing, an international marketing, design, digital and content agency helping companies differentiate, get noticed and grow in life sciences.
-
Celebrating female talent in life sciences
In this episode of Molecule to Market, you’ll go inside the outsourcing space of the global drug development sector with:
Denise Bowser from Onyx Scientific
Audrey Greenberg from SK Pharmteco
Kendalle Burlin O’Connell from MassBio
Elisabeth Stampa from Medicines For Europe
Sabina Ouimet-Storrs from GHO Capital
In this episode, we feature highlights from recent interviews with some of the most inspiring women in the life sciences industry. These women sat down with host, Raman Sehgal, to share their unique perspectives on topics including career progression, COVID-19, M&A, and the importance of diversity and inclusion in the workplace.
Listen to the full episodes:
Dealing with downturns… and the menopause with Denise Bowser
From banking to biotech with Audrey Greenberg
From MassBio… to the world with Kendalle Burlin O’Connell
Transforming a family pharma firm with Elisabeth Stampa
M&A Roundtable and 2024 Predictions with Sabina Ouimet-Storrs
Please subscribe, tell your industry colleagues, and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also appreciate a positive rating!
Molecule to Market is sponsored and funded by ramarketing, an international marketing, design, digital and content agency helping companies differentiate, get noticed and grow in life sciences.
-
The power of peptides
In this episode of Molecule to Market, you’ll go inside the outsourcing space of the global drug development sector with Alastair Hay, Vice President of Peptides at Almac Sciences.
Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with Alastair, covering:
The story behind Almac’s early bet of getting into the peptide game
Behind the scenes of the incredible growth journey of Almac from a few hundred to 7000+ people... and some insight into the secret sauce behind the success
Rising demand for peptides and what makes them so attractive and valuable for various emerging therapeutic areas
Some of the challenges in developing and manufacturing peptide-based therapeutics include environmental impact
Alastair graduated with a Ph.D. in synthetic organic chemistry from the University of Edinburgh in 1998, following his first degree in Pure and Applied Chemistry at the University of Strathclyde.
He spent 12 years on the operational side of Almac’s peptide business, heading up the non-GMP custom synthesis group and then the GMP process development group. In 2015, Alastair moved on from an operational role to provide technical support on peptide projects for Almac’s global business development team.
In 2020, Alastair took on operational responsibilities, first re-assuming leadership of the Process Development department and then ultimately being appointed Vice President, Peptides in 2021.
Please subscribe, tell your industry colleagues, and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also appreciate a positive rating!
Molecule to Market is sponsored and funded by ramarketing, an international marketing, design, digital, and content agency helping companies differentiate, get noticed, and grow in the life sciences.